The human immunodeficiency virus: Basic concepts of infection and host response

J. J. Zurlo

Research output: Contribution to journalArticle

Abstract

HIV has been with us for the last decade and is likely to remain with us for the foreseeable future. Key to the pathogenesis of this virus is its ability to strike at the very heart of the immune system, thereby rendering subsequent immunologic responses limited and inadequate. Because there are unique steps in the viral life cycle that involve virus-specific proteins, it is conceivable that antiretroviral agents can be developed, which minimally affect host cellular functions while profoundly interfering with the viral life cycle. For the moment, much of the current direction of treatment research is aimed at optimizing the use of existing antiretroviral agents. This optimization necessarily involves the testing of combinations of agents used concurrently and consecutively. The results of the zidovudine/ddC combination study have been encouraging and in part have led to the development of a large four-arm, ACTG multicenter trial comparing zidovudine alone versus ddI alone versus zidovudine in combination with ddI or ddC for the treatment of HIV-infected patients with CD4 counts between 200 and 500 cells/mm3. It is of course hoped that combination therapy will result in greater and more durable responses. Prospects for an HIV-1 vaccine have improved over the last few years as more has been learned about the molecular mechanisms of the immune response to the virus. Yet even if an effective vaccine were soon to become available, proving its effectiveness would present formidable ethical and logistical challenges. For instance, the vaccine would have to be a subunit vaccine rather than a killed or inactivated virus preparation owing to the fears of infectivity of the vaccine. What populations would be targeted for vaccination in clinical trials? For any population, study participants would surely need to be counseled on ways to prevent becoming infected. In that case, an expected low infection rate would translate into few clinical end points, thereby necessitating a large and expensive trial of long duration. Yet only when sufficient numbers of end points are reached would it be known whether or not the vaccine is effective. These are only a few of the many challenges that lie ahead in HIV therapy and vaccine development.

Original languageEnglish (US)
Pages (from-to)1159-1182
Number of pages24
JournalOtolaryngologic Clinics of North America
Volume25
Issue number6
StatePublished - 1992

Fingerprint

Zidovudine
Vaccines
HIV
Anti-Retroviral Agents
Viruses
AIDS Vaccines
Infection
Life Cycle Stages
Subunit Vaccines
Aptitude
Therapeutics
CD4 Lymphocyte Count
Population
Multicenter Studies
Fear
HIV-1
Immune System
Vaccination
Clinical Trials
Research

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

@article{2a440fc018a8439596da2502373eb281,
title = "The human immunodeficiency virus: Basic concepts of infection and host response",
abstract = "HIV has been with us for the last decade and is likely to remain with us for the foreseeable future. Key to the pathogenesis of this virus is its ability to strike at the very heart of the immune system, thereby rendering subsequent immunologic responses limited and inadequate. Because there are unique steps in the viral life cycle that involve virus-specific proteins, it is conceivable that antiretroviral agents can be developed, which minimally affect host cellular functions while profoundly interfering with the viral life cycle. For the moment, much of the current direction of treatment research is aimed at optimizing the use of existing antiretroviral agents. This optimization necessarily involves the testing of combinations of agents used concurrently and consecutively. The results of the zidovudine/ddC combination study have been encouraging and in part have led to the development of a large four-arm, ACTG multicenter trial comparing zidovudine alone versus ddI alone versus zidovudine in combination with ddI or ddC for the treatment of HIV-infected patients with CD4 counts between 200 and 500 cells/mm3. It is of course hoped that combination therapy will result in greater and more durable responses. Prospects for an HIV-1 vaccine have improved over the last few years as more has been learned about the molecular mechanisms of the immune response to the virus. Yet even if an effective vaccine were soon to become available, proving its effectiveness would present formidable ethical and logistical challenges. For instance, the vaccine would have to be a subunit vaccine rather than a killed or inactivated virus preparation owing to the fears of infectivity of the vaccine. What populations would be targeted for vaccination in clinical trials? For any population, study participants would surely need to be counseled on ways to prevent becoming infected. In that case, an expected low infection rate would translate into few clinical end points, thereby necessitating a large and expensive trial of long duration. Yet only when sufficient numbers of end points are reached would it be known whether or not the vaccine is effective. These are only a few of the many challenges that lie ahead in HIV therapy and vaccine development.",
author = "Zurlo, {J. J.}",
year = "1992",
language = "English (US)",
volume = "25",
pages = "1159--1182",
journal = "Otolaryngologic Clinics of North America",
issn = "0030-6665",
publisher = "W.B. Saunders Ltd",
number = "6",

}

The human immunodeficiency virus : Basic concepts of infection and host response. / Zurlo, J. J.

In: Otolaryngologic Clinics of North America, Vol. 25, No. 6, 1992, p. 1159-1182.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The human immunodeficiency virus

T2 - Basic concepts of infection and host response

AU - Zurlo, J. J.

PY - 1992

Y1 - 1992

N2 - HIV has been with us for the last decade and is likely to remain with us for the foreseeable future. Key to the pathogenesis of this virus is its ability to strike at the very heart of the immune system, thereby rendering subsequent immunologic responses limited and inadequate. Because there are unique steps in the viral life cycle that involve virus-specific proteins, it is conceivable that antiretroviral agents can be developed, which minimally affect host cellular functions while profoundly interfering with the viral life cycle. For the moment, much of the current direction of treatment research is aimed at optimizing the use of existing antiretroviral agents. This optimization necessarily involves the testing of combinations of agents used concurrently and consecutively. The results of the zidovudine/ddC combination study have been encouraging and in part have led to the development of a large four-arm, ACTG multicenter trial comparing zidovudine alone versus ddI alone versus zidovudine in combination with ddI or ddC for the treatment of HIV-infected patients with CD4 counts between 200 and 500 cells/mm3. It is of course hoped that combination therapy will result in greater and more durable responses. Prospects for an HIV-1 vaccine have improved over the last few years as more has been learned about the molecular mechanisms of the immune response to the virus. Yet even if an effective vaccine were soon to become available, proving its effectiveness would present formidable ethical and logistical challenges. For instance, the vaccine would have to be a subunit vaccine rather than a killed or inactivated virus preparation owing to the fears of infectivity of the vaccine. What populations would be targeted for vaccination in clinical trials? For any population, study participants would surely need to be counseled on ways to prevent becoming infected. In that case, an expected low infection rate would translate into few clinical end points, thereby necessitating a large and expensive trial of long duration. Yet only when sufficient numbers of end points are reached would it be known whether or not the vaccine is effective. These are only a few of the many challenges that lie ahead in HIV therapy and vaccine development.

AB - HIV has been with us for the last decade and is likely to remain with us for the foreseeable future. Key to the pathogenesis of this virus is its ability to strike at the very heart of the immune system, thereby rendering subsequent immunologic responses limited and inadequate. Because there are unique steps in the viral life cycle that involve virus-specific proteins, it is conceivable that antiretroviral agents can be developed, which minimally affect host cellular functions while profoundly interfering with the viral life cycle. For the moment, much of the current direction of treatment research is aimed at optimizing the use of existing antiretroviral agents. This optimization necessarily involves the testing of combinations of agents used concurrently and consecutively. The results of the zidovudine/ddC combination study have been encouraging and in part have led to the development of a large four-arm, ACTG multicenter trial comparing zidovudine alone versus ddI alone versus zidovudine in combination with ddI or ddC for the treatment of HIV-infected patients with CD4 counts between 200 and 500 cells/mm3. It is of course hoped that combination therapy will result in greater and more durable responses. Prospects for an HIV-1 vaccine have improved over the last few years as more has been learned about the molecular mechanisms of the immune response to the virus. Yet even if an effective vaccine were soon to become available, proving its effectiveness would present formidable ethical and logistical challenges. For instance, the vaccine would have to be a subunit vaccine rather than a killed or inactivated virus preparation owing to the fears of infectivity of the vaccine. What populations would be targeted for vaccination in clinical trials? For any population, study participants would surely need to be counseled on ways to prevent becoming infected. In that case, an expected low infection rate would translate into few clinical end points, thereby necessitating a large and expensive trial of long duration. Yet only when sufficient numbers of end points are reached would it be known whether or not the vaccine is effective. These are only a few of the many challenges that lie ahead in HIV therapy and vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=0026448086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026448086&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026448086

VL - 25

SP - 1159

EP - 1182

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

SN - 0030-6665

IS - 6

ER -